Get the Stockscreener App
23.35
1.23%
-0.29
After Hours:
23.35
Janux Therapeutics Inc stock is traded at $23.35, with a volume of 297.60K.
It is down -1.23% in the last 24 hours and down -10.05% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$23.64
Open:
$23.57
24h Volume:
297.60K
Relative Volume:
0.37
Market Cap:
$1.40B
Revenue:
$439.00K
Net Income/Loss:
$-105.64M
P/E Ratio:
-12.97
EPS:
-1.8
Net Cash Flow:
$-60.70M
1W Performance:
-6.11%
1M Performance:
-10.05%
6M Performance:
-27.05%
1Y Performance:
-48.31%
1-Day Range:
$23.23
$24.00
1-Week Range:
$22.90
$25.22
52-Week Range:
$21.97
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
23.35 | 1.42B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
How to integrate Janux Therapeutics Inc. into portfolio analysis toolsTrade Ideas & Scalable Portfolio Growth Methods - Newser
Should you wait for a breakout in Janux Therapeutics Inc.2025 Volatility Report & Fast Entry High Yield Tips - Newser
What moving averages say about Janux Therapeutics Inc.July 2025 Closing Moves & Safe Entry Point Identification - Newser
Can momentum traders help lift Janux Therapeutics Inc.Market Sentiment Summary & Weekly Momentum Stock Picks - Newser
How to escape a deep drawdown in Janux Therapeutics Inc.Weekly Trade Recap & Verified Technical Trade Signals - Newser
Will Janux Therapeutics Inc. stock recover after recent dropQuarterly Profit Summary & Daily Market Momentum Tracking - Newser
Can swing trading help recover from Janux Therapeutics Inc. lossesShare Buyback & Free Daily Entry Point Trade Alerts - Newser
Tools to monitor Janux Therapeutics Inc. recovery probabilityTrade Volume Summary & Daily Chart Pattern Signals - Newser
Custom strategy builders for tracking Janux Therapeutics Inc.Trade Volume Report & Risk Adjusted Swing Trade Ideas - Newser
Multi asset correlation models including Janux Therapeutics Inc.Weekly Investment Report & Entry Point Confirmation Signals - Newser
Technical signs of recovery in Janux Therapeutics Inc.Trade Ideas & Real-Time Chart Breakout Alerts - Newser
Applying Wyckoff theory to Janux Therapeutics Inc. stockQuarterly Earnings Report & Real-Time Volume Analysis - Newser
Will breakout in Janux Therapeutics Inc. lead to full recoveryWeekly Gains Report & Smart Swing Trading Techniques - Newser
Has Janux Therapeutics Inc. formed a bullish divergenceJuly 2025 Setups & Entry Point Confirmation Signals - Newser
Published on: 2025-08-26 10:09:09 - Newser
Janux Therapeutics Inc. stock daily chart insightsMarket Volume Report & Expert Curated Trade Setup Alerts - Newser
Can a trend reversal in Janux Therapeutics Inc. lead to recoveryCEO Change & Accurate Intraday Trade Tips - Newser
AI Indicators Detect Buy Opportunity in Janux Therapeutics Inc.2025 Market Sentiment & Fast Moving Stock Watchlists - beatles.ru
Using data filters to optimize entry into Janux Therapeutics Inc.Portfolio Gains Report & Risk Controlled Stock Pick Alerts - Newser
Published on: 2025-08-27 13:37:05 - Newser
Janux Therapeutics Inc. Ranks High in Smart Money Tracker2025 Big Picture & Low Volatility Stock Recommendations - beatles.ru
Live market analysis of Janux Therapeutics Inc.Insider Buying & Breakout Confirmation Trade Signals - Newser
Tick level data insight on Janux Therapeutics Inc. volatility2025 Price Targets & Low Risk Entry Point Tips - Newser
Applying Elliott Wave Theory to Janux Therapeutics Inc.Earnings Beat & Safe Entry Zone Identification - Newser
AI Tools Suggest Janux Therapeutics Inc. May Outperform This Week2025 Trading Recap & Safe Capital Growth Plans - mustnews.co.kr
Guggenheim Initiates Coverage on Janux Therapeutics with Buy Rating and $42.00 Target - AInvest
Janux Therapeutics Inc. Shows Early Signs of Technical Strength2025 EndofYear Setup & Weekly Hot Stock Watchlists - 더경남뉴스
Summit stock gets Neutral view at Piper Sandler (SMMT:NASDAQ) - Seeking Alpha
Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration - MSN
Piper Sandler initiates coverage of oncology companies (CGON:NASDAQ) - Seeking Alpha
Janux Therapeutics shares fall 2.08% intraday as Piper Sandler maintains its stance on the biopharma company. - AInvest
Combining price and volume data for Janux Therapeutics Inc.Earnings Growth Summary & Verified Stock Trade Ideas - Newser
Janux Therapeutics Inc. stock retracement – recovery analysisPortfolio Risk Report & AI Forecast Swing Trade Picks - Newser
9 Best Small Cap Stocks with Biggest Upside Potential - Insider Monkey
Is Janux Therapeutics Inc. a candidate for recovery play2025 Earnings Surprises & High Return Stock Watch Alerts - Newser
Chart based exit strategy for Janux Therapeutics Inc.Dividend Hike & AI Optimized Trading Strategy Guides - Newser
What MACD and RSI say about Janux Therapeutics Inc.Market Trend Summary & Consistent Profit Trade Alerts - Newser
Will Janux Therapeutics Inc. continue its uptrend2025 Macro Impact & AI Powered Market Trend Analysis - Newser
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):